OVID - Ovid Therapeutics

-

$undefined

N/A

(N/A)

Ovid Therapeutics NasdaqGS:OVID Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Location: 441 Ninth Avenue, New York, NY, 10001, United States | Website: https://www.ovidrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-7.169M

Cash

43.0M

Avg Qtr Burn

-12.39M

Short % of Float

3.24%

Insider Ownership

16.31%

Institutional Own.

55.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soticlestat (OV935) Details
Rare genetic disease, Rare diseases, Dravet syndrome, Lennox-Gastaut syndrome

Phase 3

Update

OV888 (GV101) Details
Cerebral cavernous malformation

Phase 2

Initiation

Phase 1

Data readout

OV935 (CH24H Inhibitor) Details
Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease

Failed

Discontinued

OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details
Genetic disorder, Rare genetic disease, Angelman Syndrome

Failed

Discontinued

OV101 (gaboxadol) Details
Rare genetic disease, Fragile X syndrome

Failed

Discontinued